Alnylam Pharmaceuticals (ALNY) News Today

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) shares are trading higher today as investors react to strong second-quarter results, raised full-year guidance, fast-track designations and a wave of analyst price-target increases, driven by rapid uptake of its Amvuttra therapy and expanding Rare Disease franchise.

• Positive Sentiment: Q2 earnings topped estimates on surprise profitability and surged Amvuttra revenues; 2025 full-year revenue guidance was raised. ALNY Q2 Earnings Top Estimates
• Positive Sentiment: FDA granted Fast Track designation for a new Amvuttra heart disease indication, boosting long-term growth outlook. FDA Fast Track Designation
• Positive Sentiment: Analysts at Needham & Company raised their price target from $377 to $478 and reiterated a Buy rating. Needham & Co. Upgrade
• Positive Sentiment: UBS Group lifted its target to $550 from $403 and maintained a Buy rating, highlighting strong pipeline momentum. UBS Raises ALNY Target
• Positive Sentiment: Barclays boosted its price target from $329 to $460 and assigned an Overweight rating. Barclays Upgrade
• Positive Sentiment: Piper Sandler raised its target from $304 to $449, citing Amvuttra’s powerful commercial launch. Piper Sandler Upgrade
• Positive Sentiment: Canaccord Genuity lifted its target to $415 from $390 and reiterated a Buy rating. Canaccord Upgrade
• Positive Sentiment: Chardan Capital raised its target from $325 to $400 and maintained a Buy rating. Chardan Upgrade
• Positive Sentiment: Raymond James initiated coverage with an Outperform rating and a $370 target. Raymond James Coverage
• Neutral Sentiment: Wells Fargo & Company set an Equal Weight rating with a $395 target, implying limited near-term upside. Wells Fargo Rating